NYSE:NUVBPharmaceuticals
Nuvation Bio (NUVB) Could Be 48% Undervalued As Safusidenib Data Strengthens Its Case
Nuvation Bio (NUVB) is in focus after updated long term Phase 2 and Phase 3 data for safusidenib in grade 2 IDH1-mutant glioma showed strong response rates and a consistent safety profile.
See our latest analysis for Nuvation Bio.
The positive safusidenib data arrives as Nuvation Bio’s share price has climbed in the short term, with a 1-month share price return of 15.65% and a 3-month gain of 25.59%. However, the year-to-date share price is still down 25.06%, while the 1-year total...